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Abstract  
 
Introduction: Adiponectin is an adipokine that regulates energy metabolism and insulin 
sensitivity, but recent studies have pointed also to a role in inflammation and arthritis. The 
purpose of the present study was to investigate the association and effects of adiponectin on 
inflammation and cartilage destruction in osteoarthritis (OA). 
Methods: Cartilage and blood samples were collected from 35 male OA patients undergoing 
total knee replacement surgery. Preoperative radiographs were evaluated by Ahlbäck 
classification criteria for knee OA. Circulating concentrations of adiponectin and biomarkers 
of OA, i.e. cartilage oligomeric matrix protein (COMP) and matrix metalloproteinase 3 
(MMP-3), were measured. Cartilage samples obtained at the surgery were cultured ex vivo 
and the levels of adiponectin, nitric oxide (NO), interleukin-6 (IL-6) and metalloproteinases 
MMP-1 and MMP-3 were determined in the culture media. In addition, the effects of 
adiponectin on the production of NO, IL-6, MMP-1 and MMP-3 were studied in cartilage and 
in primary chondrocyte cultures.  
Results: Plasma adiponectin levels and adiponectin released from OA cartilage were higher 
in patients with radiologically most severe OA (Ahlbäck grades 4-5) than in patients with less 
severe disease (grades 1-3). Plasma adiponectin concentrations correlated positively with 
biomarkers of OA, i.e. COMP (r = 0.55, p = 0.001) and MMP-3 (r = 0.34, p = 0.046). 
Adiponectin was released by OA cartilage ex vivo and it correlated positively with NO (r = 
0.43, p = 0.012), IL-6 (r = 0.42, p = 0.018), and MMP-3 (r = 0.34, p = 0.051) production. 
Further, adiponectin enhanced production of NO, IL-6, MMP-1 and MMP-3 in OA cartilage 
and in primary chondrocytes in vitro by a mitogen-activated protein kinase (MAPK) 
dependent manner. 
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Conclusions: These findings show that adiponectin is associated with and possibly mediates 
cartilage destruction in OA.  
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Introduction 
 
Adiponectin belongs to the adipokine hormones, which were initially found to be synthesized 
by white adipose tissue and to control appetite and metabolism. Adiponectin was discovered 
in 1995 by Scherer et al. and it was first named as Acrp30, adipocyte complement-related 
protein of 30 kDa [1]. Adiponectin has been found to improve insulin sensitivity [2,3] and to 
have antiatherogenic properties [4]. Interestingly, adiponectin has also been identified as a 
regulatory factor in inflammation and arthritis [5-8].  
 
Adiponectin can be found in synovial fluid from OA patients [9,10]. Tissues in the joint, 
including synovium, meniscus, osteophytes, cartilage, bone and fat have been reported to 
produce adiponectin [10-12]. The biological effects of adiponectin are mediated through two 
adiponectin receptor subtypes, adiponectin receptor type 1 (AdipoR1) and type 2 (Adipo R2), 
which have been shown to be expressed in articular cartilage, bone and synovial tissue 
[13,14].  
 
In arthritis models and in joint tissues, adiponectin has been postulated to have both pro- and 
anti-inflammatory effects. Adiponectin has been reported to increase the production of 
cartilage degrading MMP enzymes, cytokines and prostaglandin E2 in chondrocytes and in 
synovial fibroblasts [11,14-19]. By contrast, intra-articularly injected adiponectin was 
reported to mitigate the severity of collagen-induced arthritis in the mouse, and to decrease 
immunohistochemically detected expression of tumor necrosis factor, interleukin-1 and 
MMP-3 [20]. Recently, high circulating adiponectin was found to correlate with cartilage 
degradation in patients with rheumatoid arthritis (RA) [21-23] although partly contradictory 
results have also been published [24,25]. 
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Adiponectin has emerged as a regulator of immune responses and inflammatory arthritis [5-
7], but its role in OA and cartilage degradation is controversial and, in many aspects, poorly 
known. The purpose of the present study was to investigate if adiponectin is associated with 
radiographic severity or biomarkers of OA, or with inflammatory / destructive factors 
released by cartilage samples obtained from OA patients. Since MAPK pathways have been 
proposed as therapeutic targets in osteoarthritis [26,27], we decided also to study the possible 
involvement of these pathways in adiponectin-induced responses in OA cartilage. 
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Materials and methods 
 
Patients and clinical studies 
Patients fulfilled the American College of Rheumatology classification criteria for OA [28]. 
Preoperative radiographs, blood samples and cartilage tissue were collected from 35 male 
patients with OA (age 69.5 ± 1.6 years, BMI 29.3 ± 0.8 kg/m²; mean ± SEM) undergoing total 
knee replacement surgery in Coxa Hospital for Joint Replacement, Tampere, Finland. 
Radiographs were evaluated according to the Ahlbäck criteria, from grade I to V, grade V 
representing the most severe findings [29]. Plasma and serum samples were stored at -80ºC 
until analyzed for COMP, MMP-3 and adiponectin. Cartilage samples were processed as 
described below and the amounts of adiponectin, NO, IL-6, MMP-1 and MMP-3 released by 
the cartilage ex vivo during 42 h incubation were measured as described below. The study was 
approved by the Ethics Committee of Tampere University Hospital and carried out in 
accordance with the Declaration of Helsinki. Written informed consent was obtained from the 
patients. 
 
Cartilage cultures 
Leftover pieces of OA cartilage from knee joint replacement surgery were used. Full 
thickness pieces of articular cartilage from femoral condyles, tibial plateaus and patellar 
surfaces showing macroscopical features of early OA were removed aseptically from 
subchondral bone with a scalpel and cut into small pieces and cultured in Dulbecco´s 
modified Eagle´s medium (DMEM) with glutamax-I (from Lonza, Basel, Switzerland) 
supplemented with penicillin (100 units/ml), streptomycin (100 µg/ml) and amphotericin B 
(250 ng/ml) (all from Invitrogen, Carlsbad, CA, USA) at 37°C in a humidified 5% carbon 
dioxide atmosphere. 
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Cartilage samples were incubated for 42 h with or without adiponectin (Recombinant Human 
Adiponectin produced in human embryonic kidney (HEK) cells, Biovendor, Modrice, Czech 
Republic) and MAP-kinase inhibitors PD98059 (Erk1/2 inhibitor, 10 µM; from Promega, 
Madison, WI, USA), SB220025 (p38 inhibitor, 0.5 µM; from Calbiochem, Merck, Darmstadt, 
Germany) and SP600125 (JNK inhibitor, 10 µM; from Calbiochem, Merck, Darmstadt, 
Germany). The concentrations of adiponectin and MAPK inhibitors used in the experiments 
were based on preliminary experiments and studies previously carried out in our laboratory 
[30-32]. After the experiments, the cartilage explants were weighed and the results were 
expressed per mg of cartilage. The culture media were kept at -20°C until analyzed.  
 
Primary chondrocyte experiments 
Leftover pieces of OA cartilage from knee replacement surgery were used. Full thickness 
pieces of articular cartilage from femoral condyles, tibial plateaus and patellar surfaces were 
removed aseptically from subchondral bone with a scalpel and cut into fine pieces. The pieces 
were washed with phosphate buffered saline (PBS) and chondrocytes were isolated by 
enzymatic digestion for 16 h at 37°C in a shaker by using collagenase enzyme blend (1 
mg/ml; Liberase TM Research Grade from Roche, Mannheim, Germany). Isolated 
chodrocytes were washed and plated on 24-well plates (1.5 x 105 cells/ml) in culture medium 
(DMEM with supplements, see above) containing 10% of fetal bovine serum. Cells were 
treated with increasing concentrations of adiponectin (0.1-3 µg/ml) for 24 h. The culture 
media were kept at -20°C until analyzed. Concentrations of NO, IL-6, MMP-1 and MMP-3 
were determined in culture media as described below. To investigate MAP kinase activation 
(phosphorylation), cells were treated with adiponectin for 30 or 60 min and processed for 
Western blotting. 
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NO production 
Concentrations of nitrite, a stable metabolite of NO in aqueous solutions, were measured by 
the Griess reaction [33]. 
 
Measurement of adiponectin, COMP, MMP-1, MMP-3 and IL-6 
Concentrations of adiponectin, COMP, MMP-1, MMP-3 and IL-6 in plasma, serum and/or 
medium samples were determined by enzyme-linked immunosorbent assay (ELISA) by using 
commercial reagents (adiponectin, MMP-1 and MMP-3: R&D Systems, Europe Ltd, 
Abindgon, UK; COMP: Biovendor, Modrice, Czech Republic; IL-6: Sanquin, Amsterdam, 
Netherlands). 
 
Western blot analysis 
Western blot analysis was performed as previously described [34] using following antibodies: 
rabbit polyclonal anti-human iNOS, actin and JNK antibodies and HRP-conjugated goat anti-
rabbit IgG antibody from Santa Cruz Biotechnology, Inc (Santa Cruz, California, USA); 
rabbit polyclonal anti-human p38, phospho-p38, phospho-JNK, Erk1/2 and phospho-Erk1/2 
antibodies from Cell Signaling Technology, Inc (Beverly, Mass, USA).  
 
Statistical analysis 
Data were analyzed using SPSS 17.0 software for Windows (SPSS Inc., Chicago, IL, USA) 
and GraphPad Instat version 3.00 (GraphPad software, San Diego, CA, USA). The results are 
presented as mean ± standard error of mean (SEM) or as otherwise indicated. Pearson´s 
correlation analysis was carried out and r values over 0.3 and under -0.3 were considered to 
indicate a correlation. Differences between groups were tested by one-way ANOVA or by 
repeated measures ANOVA followed by LSD or Bonferroni multiple comparisons test when 
appropriate. P-values less than 0.05 were considered significant. Standard multiple regression 
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analysis was used to predict circulating biomarker levels (COMP and MMP-3) when 
adiponectin, age and BMI were set as independent variables. Unstandardized regression 
coefficients (B) and coefficient of determination squared (R2) with the related p-values were 
calculated. Binary logistic regression was used to compute (BMI or age adjusted) odds ratios 
(OR) for plasma adiponectin and adiponectin released by cartilage to predict the most severe 
radiographic findings (Ahlbäck grades 4-5 vs. grades 1-3). Statistician was consulted 
regarding the statistical analysis. 
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Results 
 
Correlation between plasma adiponectin and biomarkers of OA 
Thirty-five male OA patients were included in the study. Mean adiponectin concentration in 
plasma was 2.5 ± 0.2 µg/ml and no correlation between plasma adiponectin and BMI was 
found (r = -0.15, p = 0.379). Interestingly, adiponectin correlated positively with the 
biomarkers of OA, i.e. COMP (r = 0.55, p = 0.001; Figure 1A) and MMP-3 (r = 0.34, p = 
0.046; Figure 1B) pointing to a possible connection between adiponectin and cartilage matrix 
degradation. 
 
In multiple regression analysis, where serum COMP was set as a dependent variable and 
plasma adiponectin, age and BMI as predictive variables, adiponectin (B (i.e. expected change 
in COMP with one unit change in adiponectin) = 1.7, p = 0.010), but not BMI (B = -0.10, p = 
0.566) or age (B = 0.14, p = 0.160), was a significant determinant of COMP (R2 = 0.39, p = 
0.001 for model). Also, adiponectin was a significant determinant of MMP-3 when it was set 
alone as an independent variable (B = 0.85, p = 0.046; R2 = 0.12, p= 0.046 for model). 
Addition of BMI or age as independent variables did not improve the model (R2 = 0.15, p = 
0.070 or R2 = 0.14, p = 0.089, respectively).  
 
Plasma adiponectin levels and radiographic severity of OA  
Preoperative radiographs of the knees were evaluated by Ahlbäck classification from grade 1 
to 5, grade 5 presenting the most severe findings [29]. Grades 1-2 and 4-5 were combined in 
order to have more equally distributed subgroups. Mean plasma adiponectin concentrations 
were higher in grades 4-5 group as compared to grade 3 and grades 1-2 groups (Figure 2A) 
while there was no difference between grades 1-2 group and grade 3 group. There were no 
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significant differences in age or BMI between the radiographic subgroups, while serum 
COMP was higher in grades 4-5 group as compared to grade 3 and grades 1-2 group (p = 
0.012 and p = 0.006, respectively) (Table 1). Binary logistic regression analysis was used to 
further evaluate if adiponectin is associated with the radiographic severity of OA (Ahlbäck 
grades 4-5 group vs. 1-3 group). When set alone in the model, plasma adiponectin and 
cartilage culture medium adiponectin, but not BMI or age, were significant explanatory 
factors of radiographic severity (Table 2). After adjusting for BMI, plasma adiponectin was a 
significant predictor of disease severity and almost significant after adjusting for age (Table 
2). Adiponectin measured in the cartilage culture media was a significant predictor of OA 
severity after controlling for age and BMI (Table 2).  
 
Production of adiponectin and inflammatory / degrading factors by OA cartilage ex vivo 
Cartilage samples were obtained during joint replacement surgery from the same patients 
from whom the preoperative radiographs and the blood samples had been collected (see 
above), and tissue culture experiments were carried out. The amounts of adiponectin, NO, IL-
6, MMP-1 and MMP-3 released from the cartilage into the culture medium during 42 h 
incubation were measured. Adiponectin release was increased in patients with 
radiographically most severe OA (Ahlbäck grades 4-5) as compared to grades 1-2 and grade 3 
patients (p = 0.004 and p < 0.001, respectively; Figure 2B). Interestingly, adiponectin levels 
in the cartilage culture media correlated positively with those of NO (r = 0.43, p= 0.012; 
Figure 3A), IL-6 (r = 0.42, p = 0.018; Figure 3B) and MMP-3 (r = 0.34, p = 0.051; Figure 
3C), whereas no correlation between adiponectin and MMP-1 production was found (r = 0.17, 
p = 0.31).  
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Effect of adiponectin on OA cartilage and primary chondrocytes in vitro 
To further evaluate the role of adiponectin in OA, we studied the effect of this adipokine on 
MAP-kinase phosphorylation (i.e. activation) and on NO, IL-6, MMP-1 and MMP-3 
production in primary chondrocytes from OA patients. Adiponectin treatment resulted in 
time-dependent phosphorylation of p38, Erk1/2 and JNK in primary OA chondrocytes which 
was obvious in 30 min and decreased towards baseline in 60 min (Figure 4). Adiponectin also 
enhanced NO, IL-6, MMP-1 and MMP-3 production in primary OA chondrocytes in a dose-
dependent manner (Figure 5). Because cartilage matrix is an important regulator of 
chondrocyte metabolism, we wanted to investigate the effects of adiponectin also on OA 
cartilage in tissue culture. Because of the limited amount of tissue available for the 
experiments, one concentration of adiponectin (1 µg/ml) was selected based on the cell 
culture studies (Figure 5) and previously published data on adiponectin levels in OA synovial 
fluid [9,10,12,35]. Adiponectin enhanced NO, IL-6, MMP-1 and MMP-3 production and 
iNOS expression in OA cartilage culture and their production was suppressed by p38 MAPK 
inhibitor SB220025 (0.5 µM) (Figure 6). In addition, Erk1/2 inhibitor PD98059 (10 µM) and 
JNK inhibitor SP600125 (10 µM) inhibited adiponectin-induced production of IL-6 and NO, 
and expression of iNOS in a statistically significant manner while their effect on MMP-1 and 
MMP-3 was smaller and did not reach statistical significance (Figure 6). 
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Discussion 
 
Adiponectin is found in OA joints and proinflammatory and catabolic effects have been 
reported [9,10,13-19]. In the present study, we show for the first time that the circulating 
adiponectin concentrations correlate positively with the levels of the widely used biomarkers 
of OA, i.e. COMP and MMP-3, and that plasma adiponectin levels, and adiponectin levels 
released by cultured cartilage, are associated with the radiographic severity of OA. 
Interestingly, the amount of adiponectin released by OA cartilage ex vivo also correlated 
positively with the production of inflammatory mediators NO and IL-6, and with the matrix 
degrading enzyme MMP-3. Further, adiponectin, when added at physiological concentrations 
to cultures of intact human OA cartilage or primary OA chondrodytes, enhanced the 
production of inflammatory / destructive factors NO, IL-6, MMP-1 and MMP-3. These 
findings suggest that adiponectin is associated with cartilage matrix degradation and has a 
role in the pathogenesis or as a biomarker in OA. 
In the present study, we measured circulating levels of COMP (cartilage oligomeric matrix 
protein) and MMP-3 to evaluate the degree of on-going cartilage destruction in OA [36]. The 
level of serum COMP has been shown to correlate with the grade of OA assessed by the 
radiological score [37], which was also seen in the current study. Also, the concentrations of 
MMP-3 have been reported to associate with joint space narrowing [38]. The present results 
demonstrate for the first time that plasma adiponectin levels correlate with COMP and MMP-
3 suggesting an association between adiponectin and the degree of on-going cartilage matrix 
degradation.  
 
In the present study, we also found that plasma adiponectin levels and adiponectin amounts 
released by cultured OA cartilage ex vivo were higher in patients with radiographically 
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advanced OA (grade 4-5 according to the Ahlbäck classification) as compared to patients with 
less severe disease (grades 1-3). This further suggests that adiponectin is associated with 
cartilage degradation in patients with OA. Our results are supported by the recent studies by 
Giles et al. [22], Ebina et al. [21] and Klein-Wieringa et al. [23] showing that circulating 
adiponectin correlates with joint erosions in RA patients; and also by the study of Laurberg et 
al. [39] reporting elevated plasma adiponectin concentrations in OA patients as compared to 
healthy controls. In our study, adiponectin released by cultured cartilage also correlated 
positively with NO, IL-6 and MMP-3 production in the cartilage.  
 
Two recent studies have reported somewhat different findings on the association between 
plasma adiponectin levels and radiographic findings. In the study by Honsawek et al. [24] 
adiponectin concentrations in plasma and synovial fluid were lower in patients with more 
severe knee OA measured by Kellgren and Lawrence scaling. However, after adjustment for 
gender, age and BMI the plasma finding became non-significant but the differences between 
adiponectin levels in synovial fluid within the radiographic groups remained significant. Most 
of their patients were female, which may, at least partly, explain the differences between their 
and our results. Also, the two different radiographic scaling systems emphasize different 
findings. We chose to use Ahlbäck grading since it tends to divide the end-stage OA patients 
less roughly than Kellgren and Lawrence scaling as reported e.g. by Petersson et al [40]. 
Accordingly, most of our patients (80%) were scaled into the most severe Kellgren and 
Lawrence grade (grade 4). We included only male patients in the present study as gender is 
likely to be a confounding factor. A study by Yusuf et al. [25] revealed that higher levels of 
plasma adiponectin decreased risk for hand OA progression in a six-years follow up, 
measured by radiographic changes.  The findings of that study appear to be somewhat 
contradictory to our results and to those by the other groups reported above. The differences 
may be explained by many factors, including different methodology to measure adiponectin, 
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differences in patient characteristics and study protocol, gender differences (most of the 
patients in the study of Yusuf et al. were women), and even by possible differences in the 
pathophysiologies of hand and knee OA. It is also possible that the significance of 
adiponectin varies according to the phase/severity of the OA process. It is noteworthy that all 
our patients had advanced OA and were undergoing joint replacement surgery. This made it 
possible to obtain simultaneous cartilage and blood samples. Lack of patients with less severe 
OA, however, limits us to generalize the results to milder cases.  
 
An inverse relationship between adiponectin levels and BMI, and especially with visceral fat, 
has been reported in studies with endocrinological approach [41]. However, no correlation 
between adiponectin and BMI was found in several recent clinical studies where patients with 
OA or RA were investigated [35,39,42]. This was also the case within our group of OA 
patients. This may be explained by the fact that circulating concentrations of adiponectin can 
be regulated by various hormonal, nutritional or pharmacological factors and that adiponectin 
is produced not only by white adipose tissue, but by other tissues as well [41]. The question 
remains open whether there is such a systemic factor that affects the adiponectin levels in 
patients with arthritis, or might the joint disease itself be actually a greater explanator than 
BMI to define adiponectin levels in these patients. 
 
As the clinical data suggested that the amount of adiponectin released by cartilage is related to 
the severity of cartilage degradation, we decided to study its possible mechanisms in OA 
cartilage. In agreement with recent findings [11,14-16,18] adiponectin was found to stimulate 
human OA cartilage and primary OA chondrocytes to produce NO, IL-6, MMP-1 and MMP-
3, which are proinflammatory / catabolic mediators in OA [43-50]. Accordingly, adiponectin 
was very recently reported to increase also the production of chemokine IL-8 in human 
chondrocytes [19]. MAP kinase inhibitors are under development for treatment of OA 
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[26,27], and MAP kinase pathways have been reported to be activated by adiponectin [51,52]. 
Therefore we studied if MAP-kinase signaling pathways are activated by adiponectin also in 
articular chondrocytes and might mediate its effects on NO, IL-6, MMP-1 and MMP-3 
production. Adiponectin was found to activate p38, JNK and Erk1/2 kinases at 
physiologically relevant concentrations. P38 inhibitor decreased the production of all factors 
studied in a statistically significant manner while Erk1/2 was involved in adiponectin induced 
iNOS expression and NO production, and JNK in NO, iNOS and IL-6 production. These 
results together with recently published findings [14,18] show that MAP kinases, especially 
p38, are significant pathways in adiponectin signaling in chondrocytes. Also, MAP kinase 
inhibitors are likely to attenuate adiponectin-induced gene expression in OA cartilage.  
 
Adipokines, i.e., hormones secreted by adipose tissue have emerged to be important 
modulating agents not only in energy metabolism and appetite, but also in immune system 
and inflammation [53], and they are likely to have a role in mediating the connection between 
obesity and chronic inflammatory diseases. Actions of adiponectin, leptin, resistin and other, 
less studied adipokines in OA and other rheumatic diseases have recently been reviewed by 
Gómez et al and by Neumann et al [7,8]. The most studied adipokine in the pathophysiology 
of arthritis is leptin, which has been proven to have proinflammatory and catabolic role in OA 
[8,19,54-58]. Knowledge about adiponectin in joint diseases has accumulated only lately. The 
present results together with the other recent reports strongly suggest a proinflammatory and 
catabolic role also for adiponectin in OA and RA cartilage. 
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Conclusions 
 
Adiponectin was associated with markers and signs of cartilage degradation, i.e. with 
circulating concentrations of COMP and MMP-3 and with radiographic severity of OA. 
Adiponectin was released by OA cartilage ex vivo, and it correlated with production of NO, 
IL-6 and MMP-3, which are important mediators in the pathogenesis of OA. Subsequent in 
vitro studies demonstrated that adiponectin when added into the culture enhanced the 
production of NO, IL-6, MMP-1 and MMP-3 in OA cartilage and primary OA chondrocytes. 
Adiponectin also activated p38, Erk1/2 and JNK in chondrocytes, and the adiponectin-
induced production of NO, IL-6, MMP-1 and MMP-3 were mediated by MAP kinases, 
especially by p38. These findings strongly suggest that adiponectin is involved in the 
pathogenesis of joint inflammation and cartilage destruction in osteoarthritis and may be a 
target for disease-modifying drug development. 
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Figure legends 
 
Figure 1 Adiponectin correlates with biomarkers of OA. Scatter plots showing positive 
correlations between plasma adiponectin and biomarkers of OA, serum COMP (A) and 
plasma MMP-3 (B). N = 35 OA patients. 
 
Figure 2 Adiponectin levels in plasma and those released by cultured cartilage were 
higher in patients with radiologically more severe OA. Adiponectin levels in plasma (A) 
and the amount of adiponectin released by OA cartilage samples into culture media (B) in OA 
patients classified according to the severity of their knee OA by the Ahlbäck grading scale. 
Horizontal solid and dashed bars within the boxes represent the median and mean, 
respectively; boxes represent the interquartile range; lines outside boxes represent minimum 
and maximum. Outliers are indicated. 
 
Figure 3 Ex vivo cartilage releases adiponectin and its concentration correlates with NO, 
IL-6 and MMP-3 production. Scatter plots showing positive correlations between 
adiponectin and NO (A), IL-6 (B) and MMP-3 (C) released by OA cartilage into the culture 
medium. Cartilage samples were collected from 35 OA patients undergoing knee replacement 
surgery. 
 
Figure 4 Adiponectin induces activation of MAP kinases in human primary 
chondrocytes. The effect of adiponectin (3 µg/ml) on MAP kinase phosphorylation in human 
primary chondrocytes obtained from patients with OA. The figure shows the results of a 
representative experiment, which was repeated three times (i.e. with cells from three donors) 
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with similar results. MAP kinases were determined by Western blot analysis at baseline and at 
30 min and 60 min after addition of adiponectin.  
 
Figure 5 Adiponectin enhances NO, IL-6, MMP-1 and MMP-3 production in human 
primary chondrocytes in a dose dependent manner. Chondrocytes obtained from patients 
with OA were treated with increasing concentrations of adiponectin (0.1-3 µg/ml). 
Concentrations of NO (A), IL-6 (B), MMP-1 (C) and MMP-3 (D) were measured by the 
Griess reaction and ELISA in the culture medium after 24 h incubation. The figure shows the 
results of a representative experiment which was repeated three times (i.e. with cells from 
three donors) with similar results. Results are expressed as mean ± SEM, n = 4. * = P < 0.05, 
** = P < 0.01 and *** = P < 0.001 as compared to the control sample. 
 
Figure 6 MAP kinase pathways are involved in adiponectin induced NO, IL-6, MMP-1 
and MMP-3 production in OA cartilage. The effects of MAP kinase inhibitors on 
adiponectin-induced NO production (A), iNOS expression (B), IL-6 production (C), MMP-1 
production (D) and MMP-3 production (E) in human OA cartilage. Cartilage explants were 
incubated for 42 h with adiponectin (1µg/ml) and the inhibitor indicated. Samples were 
collected from 6 patients in A and B and from 5 patients in C, D and E. Results are expressed 
as mean ± SEM. # = P < 0.1, * = P < 0.05, ** = P < 0.01 and *** = P < 0.001 as compared to 
explants treated with adiponectin alone. PD98059 – Erk1/2 inhibitor; SB 220025 – p38 
inhibitor; SP600125 – JNK inhibitor; inhibitor concentrations used were based on previous 
studies in our laboratory [30-32]. 
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Table 1 Plasma adiponectin levels and clinical characteristics of patients in radiographic subgroups 
 
 radiograhic severity of OA by Ahlbäck classification   
 Grades 1-2 Grade 3 Grades 4-5 Total p 
 (n = 11) (n = 16) (n = 8) (n = 35)  
Adiponectin (µg/ml) 2.4 (0.4) 2.1 (0.2) 3.5 (0.5) 2.5 (0.2) 0.03 
Age (years) 68.7 (3.0) 67.3 (2.6) 75.0 (2.0) 69.5 (1.6) 0.17 
BMI (kg/m2) 28.7 (1.1) 29.8 (1.4) 29.0 (1.6) 29.3 (0.8) 0.84 
COMP (U/l) 10.6 (1.1) 11.7 (1.0) 17.0 (2.4) 12.6 (0.9) 0.01 
MMP-3 (ng/ml) 9.6 (1.1) 9.2 (0.6) 10.9 (1.5) 9.7 (0.6) 0.52 
Values are mean (SEM) 
p value refers to the significance of the comparison of the three groups calculated by ANOVA 
 
Table 2 Association of adiponectin and radiographic severity of OA. Odds ratios for beloging to Ahlbäck grades 
4-5 group vs. grades 1-3 group. 
 Crude OR 95% CI p Adjusted OR 95% CI p 
Plasma adiponectin (µg/ml) 2.2 1.1 - 4.3 0.022 2.2a 1.1 - 4.4 0.022 
    1.9b 0.9 - 3.8 0.090 
Culture media adiponectin (pg/mg cartilage) 1.1 1.0 - 1.2 0.007 1.1a 1.0 - 1.2 0.007 
    1.1b 1.0 - 1.2 0.016 
BMI (kg/m2) 1.0 0.8 - 1.2 0.852    
Age (years) 1.1 1.0 - 1.3 0.078    
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